Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma

Future Oncology

Volumn 10, Issue 6, 2014, Pages 1095-1111

  Czarnecka, Anna M ^a   Kornakiewicz, Anna ^a,b   Kukwa, Wojciech ^b   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

HIF; immunohistochemistry; molecular imaging; PBRM1; PET; renal cell cancer; VHL

Indexed keywords

CALCIUM; HEMOGLOBIN; LACTATE DEHYDROGENASE;

BLOOD CELL COUNT; CALCIUM BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CIRCULATING TUMOR CELL; CLINICAL RESEARCH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DISTANT METASTASIS; ECHOGRAPHY; GENE EXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC DISORDER; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KARYOTYPE; KIDNEY CALCIFICATION; KIDNEY CARCINOMA; KIDNEY FUNCTION TEST; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION TEST; METASTASIS; MOLECULAR DIAGNOSIS; MOLECULAR IMAGING; NEPHRECTOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; URINALYSIS; WHOLE BODY MRI; CARCINOMA, RENAL CELL; CHROMOSOME ABERRATION; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENETICS; KARYOTYPING; KIDNEY NEOPLASMS; METABOLISM; MOLECULAR PATHOLOGY; PATHOLOGY; PROCEDURES; TUMOR EMBOLISM;

ABNORMAL KARYOTYPE; CARCINOMA, RENAL CELL; DIAGNOSTIC IMAGING; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; KIDNEY NEOPLASMS; MOLECULAR IMAGING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PATHOLOGY, MOLECULAR; SEQUENCE ANALYSIS, DNA;

EID: 84903203893     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.258     Document Type: Review

References (86)

1. Fleming S, O'Donnell M. Surgical pathology of renal epithelial neoplasms: Recent advances and current status. Histopathology 36(3), 195-202 (2000
2. Higgins JP, Mckenney JK, Brooks JD, Argani P, Epstein JI. Recommendations for the reporting of surgically resected specimens of renal cell carcinoma: The Association of Directors of Anatomic and Surgical Pathology. Hum. Pathol. 40(4), 456-463 (2009
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007
4. Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: Expert consensus. Nat. Rev. Clin. Oncol. 9(6), 327-337 (2012
5. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007
6. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2012
7. Goyal R, Gersbach E, Yang XJ, Rohan SM. Differential diagnosis of renal tumors with clear cytoplasm: Clinical relevance of renal tumor subclassification in the era of targeted therapies and personalized medicine. Arch. Pathol. Lab. Med. 137(4), 467-480 (2013
8. Gore ME, Bellmunt J, Eisen T et al. Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. Eur. J. Cancer 48(7), 1038-1047 (2012
9. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat. Rev. 36(1), 16-23 (2012
10. Cheng L, Zhang S, Maclennan GT, Lopez-Beltran A, Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum. Pathol. 40(1), 10-29 (2009
11. Cifola I, Spinelli R, Beltrame L et al. Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol. Cancer 7, 6 (2008
12. Sato Y, Yoshizato T, Shiraishi Y et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45(8), 860-867 (2013
13. Escudier B, Eisen T, Porta C et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl. 7), vii65-vii71 (2012
14. Motzer RJ. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Crit. Rev. Oncol. Hematol. 46(Suppl.), S33-S39 (2003
15. Patil S, Figlin RA, Hutson TE et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 22(2), 295-300 (2011
16. Motzer RJ, Escudier B, Bukowski R et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br. J. Cancer 108(12), 2470-2477 (2013
17. Choi Y, Park B, Kim K et al. Erythrocyte sedimentation rate and anaemia are independent predictors of survival in patients with clear cell renal cell carcinoma. Br. J. Cancer 108(2), 387-394 (2013
18. Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: The 2010 update. Eur. Urol. 58(3), 398-406 (2010
19. Motzer RJ, Agarwal N, Beard C et al. NCCN clinical practice guidelines in oncology: Kidney cancer. J. Natl Compr. Canc. Netw. 7(6), 618-630 (2009
20. Sun M, Shariat SF, Cheng C et al. Prognostic factors and predictive models in renal cell carcinoma: A contemporary review. Eur. Urol. 60(4), 644-661 (2011
21. Morrissey JJ, London AN, Luo J, Kharasch ED. Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin. Proc. 85(5), 413-421 (2010
22. Alves G, Pereira DA, Sandim V et al. Urine screening by Seldi-Tof, followed by biomarker identification, in a Brazilian cohort of patients with renal cell carcinoma (RCC). Int. Braz. J. Urol. 39(2), 228-239 (2013
23. Raimondo F, Morosi L, Corbetta S et al. Differential protein profiling of renal cell carcinoma urinary exosomes. Mol. Biosyst. 9(6), 1220-1233 (2013
24. Bosso N, Chinello C, Picozzi SC et al. Human urine biomarkers of renal cell carcinoma evaluated by ClinProt. Proteomics Clin. Appl. 2(7-8), 1036-1046 (2008
25. Kim K, Aronov P, Zakharkin SO et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol. Cell. Proteomics 8(3), 558-570 (2009
26. Campbell SC, Novick AC, Belldegrun A et al. Guideline for management of the clinical T1 renal mass. J. Urol. 182(4), 1271-1279 (2009
27. Heidenreich A, Ravery V. Preoperative imaging in renal cell cancer. World J. Urol. 22(5), 307-315 (2004
28. Guo HF, Song Y, Na YQ. Value of abdominal ultrasound scan, CT and MRI for diagnosing inferior vena cava tumour thrombus in renal cell carcinoma. Chin. Med. J. 122(19), 2299-2302 (2009
29. Muselaers S, Mulders P, Oosterwijk E, Oyen W, Boerman O. Molecular imaging and carbonic anhydrase IX-Targeted radioimmunotherapy in clear cell renal cell carcinoma. Immunotherapy 5(5), 489-495 (2013
30. Luczynska E, Dyczek S, Heinze-Paluchowska S et al. Nephrectomy or nephron-sparing surgery-how to decide?. Contemp. Oncol. (Pozn) 17(1), 88-93 (2013
31. Guimaraes AR, Tabatabei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology 71(4), 708-712 (2008
32. Hammett J, Ko J, Byrd N, Crispen PL, Krupski TL. Patterns of care for renal surgery: Underutilization of nephron-sparing procedures. Can. Urol. Assoc. J. 7(56), e386-e392 (2013
33. Gilet AG, Kang SK, Kim D, Chandarana H. Advanced renal mass imaging: Diffusion and perfusion MRI. Curr. Urol. Rep. 13(1), 93-98 (2012
34. Jung YS, Lee SJ, Yoon MH, Ha NC, Park BJ. Estrogen receptor alpha is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions. Cell Cycle 11(23), 4462-4473 (2012
35. Notohamiprodjo M, Staehler M, Steiner N et al. Combined diffusion-weighted, blood oxygen level-dependent, and dynamic contrast-enhanced MRI for characterization and differentiation of renal cell carcinoma. Acad. Radiol. 20(6), 685-693 (2013
36. Cornfeld D, Sprenkle P. Multiparametric MRi: Standardizations needed. Oncology (Williston Park) 27(4), 277-280 (2013
37. Mccann TE, Kosaka N, Turkbey B, Mitsunaga M, Choyke PL, Kobayashi H. Molecular imaging of tumor invasion and metastases: The role of MRI. NMR Biomed. 24(6), 561-568 (2011
38. Sufana Iancu A, Colin P, Puech P et al. Significance of ADC value for detection and characterization of urothelial carcinoma of upper urinary tract using diffusion-weighted MRI. World J. Urol. 31(1), 13-19 (2013
39. Zhang YL, Yu BL, Ren J et al. EADC values in diagnosis of renal lesions by 3.0 T diffusion-weighted magnetic resonance imaging: Compared with the ADC values. App. Magn. Reson. 44(3), 349-363 (2013
40. Ferda J, Ferdova E, Hora M et al. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: A role in treatment decisions and prognosis estimation. Anticancer Res. 33(6), 2665-2672 (2013
41. Aurangabadkar H, Ali Z. Unusual metastatic sites from renal cell carcinoma detected by 18F-FDG PET/CT scan. Clin. Nucl. Med. 38(12), e471-e473 (2013
42. Lee HC, Zhou C, Cohen DW et al. Integrated optical coherence tomography and optical coherence microscopy imaging of ex vivo human renal tissues. J. Urol. 187(2), 691-699 (2012
43. Barwari K, De Bruin DM, Faber DJ, Van Leeuwen TG, De La Rosette JJ, Laguna MP. Differentiation between normal renal tissue and renal tumours using functional optical coherence tomography: A Phase I in vivo human study. BJU Int. 110(8 Pt B), e415-e420 (2012
44. Couapel JP, Senhadji L, Rioux-Leclercq N et al. Optical spectroscopy techniques can accurately distinguish benign and malignant renal tumours. BJU Int. 111(6), 865-871 (2013
45. Macis G, Di Giovanni S, Di Franco D, Bonomo L. [Future perspectives for diagnostic imaging in urology: From anatomic and functional to molecular imaging]. Urologia 80(1), 29-41 (2013
46. Streeter JE, Gessner R, Miles I, Dayton PA. Improving sensitivity in ultrasound molecular imaging by tailoring contrast agent size distribution: In vivo studies. Mol. Imaging 9(2), 87-95 (2010
47. Kotopoulis S, Postema M. Microfoam formation in a capillary. Ultrasonics 50(2), 260-268 (2010
48. Pochon S, Tardy I, Bussat P et al. BR55: A lipopeptide-based VEGFR2-Targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest. Radiol. 45(2), 89-95 (2010
49. Horie S, Chen R, Li L, Mori S, Kodama T. Contrast-enhanced high-frequency ultrasound imaging of early stage liver metastasis in a preclinical mouse model. Cancer Lett. 339(2), 208-213 (2013
50. Stillebroer AB, Franssen GM, Mulders PF et al. Immunopet imaging of renal cell carcinoma with I-And Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Cancer Biother. Radiopharm. 28(7), 510-515 (2013
51. Shannon BA, Cohen RJ, De Bruto H, Davies RJ. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J. Urol. 180(4), 1257-1261; discussion 1261 (2008
52. Abou Youssif T, Tanguay S. Nephrectomy is necessary in the treatment of metastatic renal cell carcinoma. Can. Urol. Assoc. J. 4(1), 65-67 (2010
53. Halbert RJ, Figlin RA, Atkins MB et al. Treatment of patients with metastatic renal cell cancer: A RAND Appropriateness Panel. Cancer 107(10), 2375-2383 (2006
54. Lemos GC, Apezzato M, Borges LL, Colombo JR Jr. Robotic-Assisted partial nephrectomy: Initial experience in South America. Int. Braz. J. Urol. 37(4), 461-467 (2011
55. Wang W, Xu J, Adams TS, Tian Y, Lv W. Pure retroperitoneal laparoscopic radical nephrectomy for left renal cell carcinoma with differential extensions of level I renal vein tumor thrombus. J. Endourol. 28(3), 312-317 (2013
56. Castillo OA, Lopez-Fontana G, Vidal-Mora I, Aleman E, Aranguren G. Laparoscopic partial nephrectomy: An experience in 227 cases. Actas Urol. Esp. 38(2), 109-114 (2013
57. Remzi M, Marberger M. Renal tumor biopsies for evaluation of small renal tumors: Why, in whom, and how?. Eur. Urol. 55(2), 359-367 (2009
58. Vrdoljak E, Ciuleanu T, Kharkevich G et al. Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region. Expert Opin. Pharmacother. 13(2), 159-174 (2012
59. Volpe A, Finelli A, Gill IS et al. Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur. Urol. 62(3), 491-504 (2012
60. Lopez JI. Renal tumors with clear cells. A review. Pathol. Res. Pract. 209(3), 137-146 (2013
61. Moch H. An overview of renal cell cancer: Pathology and genetics. Semin. Cancer Biol. 23(1), 3-9 (2013
62. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166(1), 63-67 (2001
63. Galli R, Sablinskas V, Dasevicius D et al. Non-linear optical microscopy of kidney tumours. J. Biophotonics 7(1 2), 23-27 (2013
64. Algaba F, Akaza H, Lopez-Beltran A et al. Current pathology keys of renal cell carcinoma. Eur. Urol. 60(4), 634-643 (2011
65. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch. Pathol. Lab. Med. 135(1), 92-109 (2011
66. Bonsib SM. Risk and prognosis in renal neoplasms. A pathologist's prospective. Urol. Clin. North Am. 26(3), 643-660, viii (1999
67. Kidney Cancer: Principles and Practice. Lara PN, Jonasch E (Eds). Springer, Berlin, Germany (2012
68. Hong B, Zu Y. Detecting circulating tumor cells: Current challenges and new trends. Theranostics 3(6), 377-394 (2013
69. Cen P, Ni X, Yang J, Graham DY, Li M. Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim. Biophys. Acta 1826(2), 350-356 (2012
70. Gradilone A, Iacovelli R, Cortesi E et al. Circulating tumor cells and "suspicious objects" evaluated through CellSearch(R) in metastatic renal cell carcinoma. Anticancer Res. 31(12), 4219-4221 (2011
71. Castro CM, Ghazani AA, Chung J et al. Miniaturized nuclear magnetic resonance platform for detection and profiling of circulating tumor cells. Lab. Chip 14(1), 14-23 (2013
72. Lee HJ, Cho HY, Oh JH et al. Simultaneous capture and in situ analysis of circulating tumor cells using multiple hybrid nanoparticles. Biosens. Bioelectron. 47, 508-514 (2013
73. Zhang H, Fu X, Hu J, Zhu Z. Microfluidic bead-based multienzyme- nanoparticle amplification for detection of circulating tumor cells in the blood using quantum dots labels. Anal. Chim Acta 779, 64-71 (2013
74. Kovacs G. Molecular genetics of human renal cell tumours. Nephrol. Dial. Transplant. 11(Suppl. 6), 62-65 (1996
75. Kovacs G, Frisch S. Clonal chromosome abnormalities in tumor cells from patients with sporadic renal cell carcinomas. Cancer Res. 49(3), 651-659 (1989
76. Arai E, Ushijima S, Tsuda H et al. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: Its association with DNA methylation alteration and patient outcome. Clin. Cancer Res. 14(17), 5531-5539 (2008
77. Moore LE, Jaeger E, Nickerson ML et al. Genomic copy number alterations in clear cell renal carcinoma: Associations with case characteristics and mechanisms of VHL gene inactivation. Oncogenesis 1, e14 (2012
78. Chen M, Ye Y, Yang H et al. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int. J. Cancer 125(10), 2342-2348 (2009
79. Takahashi M, Rhodes DR, Furge KA et al. Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc. Natl Acad. Sci. USA 98(17), 9754-9759 (2001
80. Zorn KK, Bonome T, Gangi L et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11(18), 6422-6430 (2005
81. Wozniak MB, Le Calvez-Kelm F, Abedi-Ardekani B et al. Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States. PloS ONE 8(3), e57886 (2013
82. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456), 43-49 (2013
83. Vieira De Ribeiro AJ, Sandim V, Ornellas AA, Reis RS, Domont G, Alves G. Differencial proteome of clear-cell renal cell carcinoma (ccRCC) tissues. Int. Braz. J. Urol. 39(1), 83-94 (2013
84. Nagaprashantha LD, Talamantes T, Singhal J et al. Proteomic analysis of signaling network regulation in renal cell carcinomas with differential hypoxia-inducible factor-2alpha expression. PloS ONE 8(8), e71654 (2013
85. Morgan TM, Seeley EH, Fadare O, Caprioli RM, Clark PE. Imaging the clear cell renal cell carcinoma proteome. J. Urol. 189(3), 1097-1103 (2013
86. Masui O, White NM, Desouza LV et al. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol. Cell. Proteomics 12(1), 132-144 (2013.